

How Can You Beat the Shark: The US Legal Battle of Pharma and Biotech

Regulatory guidance given at the SMi's 7 annual Biosimilars Europe Conference Next Month

LONDON, ENGLAND, UNITED KINGDOM, August 23, 2016 /EINPresswire.com/ -- Jim Nelson, Senior Shareholder and Principal from intellectual property lawyers, Schwegman Lundberg Woessner, will be discussing litigation battles between pharma and biotech at SMi's 7th annual <u>Biosimilars Europe</u> conference when it returns to Central London next month.

With over 40 years of experience in the intellectual property field, the business concentration of his practice involves small to medium size pharma and biotech companies. Jim has presented talks on IP prosecution, opinion and litigation practice at pharmaceutical and chemical conferences and intellectual property organizations and associations throughout the world.

Taking a global look at traditional and new markets, his <u>keynote</u> at Biosimilars Europe 2016 will give regulatory guidance on IPR proof patents and explore alternatives to BPCIA.

When asked about the upcoming show and importance of biosimilar drug development, he said:

"Schwegman has been a sponsor of SMI conferences on pharmaceutical generics and biological biosimilars for many years. Schwegman has found that though cooperation and work with companies in





the industry that research can lead to breakthroughs in development of the drug, often making it better as well as more affordable. These breakthroughs are as important as the original development of the drug."

٢٢

"Schwegman has been a sponsor of SMI conferences on pharmaceutical generics and biological biosimilars for many years."

Schwegman Lundberg Woessner "For a company in this position, it is important to understand that the company should protect this breakthrough by procurement of intellectual property covering the development. While this may seem an oxymoron for companies in this business, such developments happen frequently and lead to advancement of treatment of disease. The IP protection helps promote further scientific development."

Biosimilars Europe 2016 will take place on 29th and 30th September at the Holiday Inn Kensington Forum in Central

London. The programme will also include expert insight from the Austrian Agency for Health and Food Safety, the Irish Health Products Regulatory Authority, the Norwegian Medicines Agency, Bristows LLP, Boehringher Ingelheim, Firstword, IMS Health, Abzena, Shanghai CP Guojian Pharmaceuticals, Merck Group, Lupin Limited and more.

Further information including a detailed agenda and full speaker line-up is available online at <u>www.biosimilars-europe.com</u>

7thth Annual Biosimilars Europe Conference 29th-30th September 2016 Holiday Inn Kensington Forum, London, UK Sponsored by Abzena and Schwegman Lundberg Woessner

--- end ---

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk To register for the conference, visit <u>www.biosimilars-europe.com</u> or contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri SMi Group 2078276000 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist

you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2016 IPD Group, Inc. All Right Reserved.